anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an adhesive band for treating lymphnoditis. The adhesive band comprises an adhesive band body (1). A group of intermittent sticking strips (4) is arranged on each of four sides of the adhesive band body (1). A cataplasm (2) used for drug adhesion is arranged on the cloth face of the adhesive band body (1). A piece of pre-arranging paper (3) facilitating plaster placement is pre-arranged on each of four sides of the cataplasm (2). After the pre-arranging paper (3) is removed, a frame of the cataplasm (2) can be adhered to skin. A plaster, prepared by smashing Dioscorea Opposita, Pellionia Radicans, Ficus Pumila, Moghania Fluminalis, Streptopus Obtusatus, Hosta Plantaginea Aschers, Polygonum Orientale, water chestnut seed powder and umbrella plant seed powder according to the ratio of 2:1:1:1:1:1:1:1:1, is arranged on the cataplasm (2). The pre-arranging paper (3) and the intermittent sticking strips (4) on the adhesive band body (1) can play a role in prevention of allergy at adhesion positions. The adhesive band has the advantages of fitness in adhesion, low production cost, quick action and good curative effect.
The American Academy of Pediatrics (AAP) recommends a staged approach to the management of pediatric overweight and obesity, starting with Stage 1, Prevention Plus, which encourages families to improve lifestyle choices related to eating and activity in order to improve BMI status. Most pediatric practices, however, have difficulty implementing these guidelines due to limited time and access to weight loss experts to whom they can refer their patients and families, and burden to families in accessing in-person weight loss services. In response, The investigators team developed the FITLINE pediatric practice-based referral program that provides practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes two components. The first, a pediatric practice-based component, consists of systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist. The second, a parent support component, consists of six weekly FITLINE counseling telephone calls delivered by centrally located nutritionists who provide tailored, personalized coaching, along with a parent booklet to guide parents in setting goals and working with their child to make Stage 1 lifestyle changes. Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention. A nonrandomized intervention study with contemporaneous control was used. Parents and their children ages 8-12 with BMI ≥85th percentile (N=40) were recruited from two pediatric practices. Practices implemented systems to identify overweight/obese children, prompt brief provider intervention, and refer parents to 6-weekly FITLINE telephone counseling sessions with a nutritionist who guided parents in setting goals and helping their child make American Academy of Pediatrics (AAP)-recommended lifestyle changes. Child BMI and parent survey of child diet and physical activity were completed at baseline and 3 months. Medical record data from 44 children matched for age and BMI was collected.
In prepn. of egg oil from hen's and/or other eggs, pref. cooled to low temp. or shock-frozen, (a) hydrocarbons, pref. white spirit and/or turpentine, and opt. water and/or alcohol, are added to and mixed with sepd. egg yolk or egg white, (b) the mixt. is heated with continuous movement, until (c) the egg oil, with residual solvent, settles on the surface of the mixt. and is sepd. from the rest of the mixt.. USE/ADVANTAGE - (i) The residual mixt. and/or oily/waxy components are used in prodn. of artists' materials, (ii) egg yolk oil is used in paints and artists' materials to alter the consistency, (iii) egg white oil is used to reinforce the luminosity of paints and lacquers, (iv) egg yolk oil and egg white oil are mixed with drying oils, resin solns., glycerides, solvents, water, binders, emulsions, lacquers, adhesives and synthetics, as protectants and impregnants, (v) egg yolk oil is used as coolant and lubricant, and (vi) egg yolk oil is used as basis for cosmetics, and for compsns. for care and polish of metal or lacquered surfaces. Other applications are: (vii) extractant for obtaining extracts from dried fruit, comprising a mixt. of egg yolk oil, balsam turpentine oil and distilled water, (viii) emulsion paint, as artists' material, comprising a mixt. of egg white oil with an acrylic binder, and opt. with hydrolysed starch, pref. rice starch, (ix) protectant and impregnant for wood comprising a mixt. of 1 pts. of egg white oil and 5-20 pts. of amaryllis oil, and (x) compsn. for coating printing plates comprising an egg oil emulsion with 10-25 vols.% of porcelain powder in distilled water and/or copa lacquer. Eggs are used industrially in a simple process. The oils can be mixed at once, hot or cold, with the emulsions, binders, artists' materials, pastes or ointments, giving good viscosity, uniformity, stability and keeping properties. Egg yolk oil combines high heat resistance, good heat conductivity and high specific heat with good slip and lubricant action. The wood protectant is liq. and easily sprayed, and has good preservative power. The compsn. for coating printing plates is a paste, easily applied with a spatula, and very hard after baking
Students in both experimental groups were applied the student information form and the pretest of the CRCF between May 18 and 20, 2021 before the education. The schedule of the education intervention was determined according to the convenience of the students in the experimental group. Accordingly, the experimental group was given education between June 8 and 11, 2021. After the education sessions were completed, experimental groups were applied the CRCF as a posttest on June 28, 2021. The students in the experimental group were asked to fill out the "Student Satisfaction with Education Questionnaire" and the "Form for Views on the Education" online.
OBJECTIVE: Brain microvascular endothelial cells (BMECs) were found to shift from their usually inactive state to an active state in ischemic stroke (IS) and cause neuronal damage. Ginsenoside Rb1 (GRb1), a component derived from medicinal plants, is known for its pharmacological benefits in IS, but its protective effects on BMECs have yet to be explored. This study aimed to investigate the potential protective effects of GRb1 on BMECs.
METHODS: An in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model was established to mimic ischemia-reperfusion (I/R) injury. Bulk RNA-sequencing data were analyzed by using the Human Autophagy Database and various bioinformatic tools, including gene set enrichment analysis (GSEA), Gene Ontology (GO) classification and enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, protein-protein interaction network analysis, and molecular docking. Experimental validation was also performed to ensure the reliability of our findings.
RESULTS: Rb1 had a protective effect on BMECs subjected to OGD/R injury. Specifically, GRb1 was found to modulate the interplay between oxidative stress, apoptosis, and autophagy in BMECs. Key targets such as sequestosome 1 (SQSTM1/p62), autophagy related 5 (ATG5), and hypoxia-inducible factor 1-alpha (HIF-1α) were identified, highlighting their potential roles in mediating the protective effects of GRb1 against IS-induced damage.
CONCLUSION: GRbl protects BMECs against OGD/R injury by influencing oxidative stress, apoptosis, and autophagy. The identification of SQSTM1/p62, ATG5, and HIF-1α as promising targets further supports the potential of GRb1 as a therapeutic agent for IS, providing a foundation for future research into its mechanisms and applications in IS treatment.
Risk Summary

Hydrocodone is present in human milk. A published lactation study reports variable concentrations of hydrocodone and hydromorphone (an active metabolite) in breast milk with administration of immediate-release hydrocodone to nursing mothers in the early post-partum period. This lactation study did not assess breastfed infants for potential adverse drug reactions. Lactation studies have not been conducted with hydrocodone bitartrate extended-release tablets, and no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with hydrocodone bitartrate extended-release tablets. 

Clinical Considerations

Monitor infants exposed to hydrocodone bitartrate extended-release tablets through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
<P>PROBLEM TO BE SOLVED: To develop a method for promoting penetration of a water-soluble medicine by applying it from the outside of the skin without utilizing a direct current electric source (cell) though it is a method for promoting penetration of a medicine by utilizing a potential gradient.  <P>SOLUTION: A method for promoting penetration of a medicine ionizing in an aqueous solution is provided. The method comprises a step for applying the medicine to the skin, and a subsequent step for applying to the skin a mixed liquid, with the medicine, of a particle having a charge repelling the ionized medicine in the aqueous solution. The medicine can be 4-methoxysalicilic acid or a salt thereof in the method. The kit comprises the mixture, with the particle, of the medicine having a negative charge in an aqueous solution and the medicine, and is used for carrying out the method by applying the aqueous solution of the medicine to the skin after a treatment for temporarily decreasing barrier functions of the skin and subsequently applying the aqueous solution of the mixture to the skin.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Casitas B-lineage lymphoma (CBL) encodes an adaptor protein with E3-ligase activity negatively controlling intracellular signaling downstream of receptor tyrosine kinases. Somatic CBL mutations play a driver role in a variety of cancers, particularly myeloid malignancies, whereas germline defects in the same gene underlie a RASopathy having clinical overlap with Noonan syndrome (NS) and predisposing to juvenile myelomonocytic leukemia and vasculitis. Other features of the disorder include cardiac defects, postnatal growth delay, cryptorchidism, facial dysmorphisms, and predisposition to develop autoimmune disorders. Here we report a novel CBL variant (c.1202G>T; p.Cys401Phe) occurring de novo in a subject with café-au-lait macules, feeding difficulties, mild dysmorphic features, psychomotor delay, autism spectrum disorder, thrombocytopenia, hepatosplenomegaly, and recurrent hypertransaminasemia. The identified variant affects an evolutionarily conserved residue located in the RING finger domain, a known mutational hot spot of both germline and somatic mutations. Functional studies documented enhanced EGF-induced ERK phosphorylation in transiently transfected COS1 cells. The present findings further support the association of pathogenic CBL variants with immunological and hematological manifestations in the context of a presentation with only minor findings reminiscent of NS or a clinically related RASopathy.
The open one of the present invention treats phthisical Chinese herbal medicine, belongs to the technical field of Chinese herbal medicine processing.Radix Cirsii Japonici, Francolini pintadeani, Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz., Rhizoma Polygonati, PINGDIMU, Gypsum Fibrosum, Radix Glycyrrhizae, Folium et Cacumen Artemisiae Halodendri seed, EM original solution etc. is used to be prepared from.Francolini pintadeani nourishes qi-restoratives appetizing and reduces phlegm, Radix Cirsii Japonici cooling blood for hemostasis clots absorbing detumescence and promoting granulation evacuation of pus, is especially suitable for the lunger that prolonged illness is weak, clear, cool, mend double executing and be able to the best favourable turn.Rhizoma Polygonati nourishing YIN and moistening the lung invigorating the spleen and replenishing QI, the detumescence of Ampelopsis cantoniensis （Hook. et Arn.） Planch. var. grossedentata Hand.-Mazz. clearing heat, detoxicating, dispelling dampness, all medicine compatibilities definitely effectively treat pulmonary tuberculosis disease for old complaint and symptom.Medicine oral administration and externally treatment pulmonary tuberculosis, is more beneficial for health quick recovery.
The invention relates to a traditional Chinese medicine composition for vision rehabilitation and a preparation method thereof. In the prior art, the processes all have the problems that the processes are coarse, the prepared preparations are instable, the contents of active constituents are low and the treatment effect in the course of practical application is unsatisfied. The composition is prepared from the following 24 traditional Chinese medicines: antelope horn, caltrop, equisetum, chrysanthemum, plantain seed, selfheal, cassia seed, ginseng, cornel (prepared), dendrobe, wolfberry fruit, dodder, glossy privet fruit, abalone shell, coptis root, pipewort, fiveleaf akebia, prepared rehmannia root, yam, alisma, poria, moutan bark, radix rehmanniae and betel palm. The process is advanced, the content of active constituents is high and the preparation has good stability. The composition has the efficacies of nourishing liver and kidney, nourishing yin, promoting the production of the body fluid, removing heat from the liver, and improving eyesight, and is mainly used for patients having the symptoms of photophobia, blurred vision, glaucoma and primary and medium cataract caused by deficiency of liver-yin and kidney-yin. The clinic pharmacodynamic test effect is obviously improved, the bioavailability is high and no toxic or side effect is generated.
Prophylactic human papillomavirus (HPV) vaccines against cervical cancer were successfully developed; however, challenges such as high cost and low compliance still remain to be overcome. In addition, because many HPV types can cause cervical cancer, antigens of multiple HPV types are needed to achieve broad protection. In this study, a bivalent single-injection HPV vaccine was designed in which virus-like particles (VLPs) of HPV 16 L1 and HPV 18 L1 were used as antigens. A recently developed drug carrier that uses tannic acid/polyethylene glycol films as the erodible layer was employed to accomplish multiple pulsatile releases of the antigens. Monovalent single-injection vaccines for HPV 16 and HPV 18 were first designed. A bivalent single-injection vaccine was then obtained by simply mixing the two monovalent vaccines. The bivalent vaccine provided protection against both HPV types. More importantly, it elicited both humoral and cellular immune responses as potent as those elicited by the corresponding multiple dose vaccine because of their similar release profile of antigens. Cross-reactivity was observed between HPV 16 and 18 in terms of cellular immune responses, while no cross-reactivity was found in terms of humoral immune responses. Note that other multivalent single-injection vaccines could be designed in the same way. These vaccines are expected to help prevent cervical cancer because of their broad protection, enhanced compliance and lowered vaccination cost.
After the polyclinic controls of the patients, on the day of the CAG procedure, data collection forms will be applied in the CAG unit 30 minutes before the procedure. Routine care will be applied to patients in this group and music therapy will not be applied. The physiological parameters of the patient will be measured by the clinical nurse 15 minutes after the procedure, and data collection forms will be applied again 20 minutes later.
INTRODUCTION AND AIM: Patients treated with HoLEP are frequently treated with previous treatments, including 5-alpha-reductase inhibitors (5-ARIs). We investigated the impact of pretreatment with 5-ARIs on perioperative and immediate postoperative parameters in patients treated with HoLEP.
MATERIAL AND METHODS: A retrospective study was performed using a prospectively collected database including all patients treated with HoLEP at our center between January 2017 and January 2023. The resected tissue weight, enucleation and morcellation efficiency (enucleation weight/time and morcellation weight/ time), postoperative complications, hospital stay and hemoglobin drop have been analyzed.
RESULTS: A total of 327 patients were included. Of these, 173 (52.9%) were treated with 5-ARIs. No differences were found among the perioperative parameters investigated to determine efficiency. No differences were observed in peri- or postoperative complications, hospital stay or hemoglobin drop.
CONCLUSIONS: Therapy with 5-ARIs had no impact on the immediate postoperative outcomes of patients treated with HoLEP. In our cohort, we observed that the use of 5-ARIs did not affect surgical efficiency, enucleation or morcellation. Further multicenter studies will be necessary to validate these findings.
Early detection of sepsis is key to ensure timely clinical intervention. Since very few end-to-end pipelines are publicly available, fair comparisons between methodologies are difficult if not impossible. Progress is further limited by discrepancies in the reconstruction of sepsis onset time. This retrospective cohort study highlights the variation in performance of predictive models under three subtly different interpretations of sepsis onset from the sepsis-III definition and compares this against inter-model differences. The models are chosen to cover tree-based, deep learning, and survival analysis methods. Using the MIMIC-III database, between 867 and 2178 intensive care unit admissions with sepsis were identified, depending on the onset definition. We show that model performance can be more sensitive to differences in the definition of sepsis onset than to the model itself. Given a fixed sepsis definition, the best performing method had a gain of 1-5% in the area under the receiver operating characteristic (AUROC). However, the choice of onset time can cause a greater effect, with variation of 0-6% in AUROC. We illustrate that misleading conclusions can be drawn if models are compared without consideration of the sepsis definition used which emphasizes the need for a standardized definition for sepsis onset.
Prior to hospital discharge, patients receive CGM application and education on how to apply the CGM, and how to use the sensor and its associated smart phone app. Patients also receive basic diabetes mellitus education. After hospital discharge, patients use CGM for up to 28 days.
BACKGROUND: Recent advancements in and the proliferation of autonomous mobility technology, such as intelligent wheelchairs, have made it possible to provide mobility services for patients with reduced mobility due to musculoskeletal disorders. In the present study, we conducted a preliminary clinical study to assess the safety and feasibility of in-hospital autonomous transportation using a driverless mobility (wheelchair) for patients with musculoskeletal disorders.
METHODS: From January to February 2022, 51 patients with musculoskeletal disorders exhibiting gait disturbance who presented to our institution were included in the present study. Driverless mobility rides were conducted over a straight-line distance of 100 m from the orthopaedic outpatient reception to the payment counter after the outpatient consultation. We assessed the quality of life using an EQ-5D-5 L index and pain using a VAS score before riding the mobility to investigate the patient's condition. After the ride, a questionnaire survey was conducted to assess patient satisfaction on a 5-point scale. In addition, adverse events during the mobility ride were investigated.
RESULTS: Overall satisfaction levels showed that 44 out of 51 (86%) patients rated the level as 3 or higher. There were no significant differences in the level of satisfaction based on the cause of disorders or EQ-5D-5 L Index. Among 19 patients who rated the level of satisfaction as 2-3, the ratio of postoperative patients and those with pain tended to be higher (p < 0.05). While 26 of 51 (51%) patients reported moments of feeling unsafe during the mobility ride, no actual adverse events, such as collisions, were observed.
CONCLUSIONS: An in-hospital autonomous transportation service using a driverless mobility for patients with musculoskeletal disorders demonstrated high satisfaction levels and was safe with no severe adverse events observed. The expansion of autonomous mobility deployment is expected to achieve mobility as a service in medical care.
The inventive curing method for a pathologic syndrome consists in inserting into an organism activated forms of minute antibody doses which are produced by means of a repeated successive dilution and an external action carried out on an antigen, e.g. a substance or medicinal preparation influencing a mechanism forming said pathologic syndrome. The inventive medicinal preparation for curing the pathologic syndrome comprises an activated form of minute doses of monoclonal, polyclonal or natural antibodies. Said antibodies are produced by means of a repeated successive dilution and an external action, preferably using homeopathic technology, which is carried out on an antigen, e.g. a substance or medicinal preparation directly promoting the formation of the pathologic syndrome or participating in regulating mechanisms for the formation thereof. Activated forms of minute doses of antibodies to the antigens of an exogenic and endogenic nature, autoantigens and fetal antigens, are used. Anti-idiotypic antibodies are also used.
Participants 21 years and older within the targeted astigmatism range and in need of cataract extraction in both eyes were consented and randomized in a 2:1 ratio at each investigative site to receive either the AcrySof® IQ ReSTOR® Multifocal Toric IOL or the control AcrySof® ReSTOR® Multifocal IOL in both eyes. Each participant completed a preoperative examination of both eyes, implantation of the IOL at the operative visit for each eye, and up to 8 postoperative visits, with monocular testing at Day 1-2, Day 7-14, and Day 30-60 and binocular testing at Day 120-180 and Day 340-420/Visit 5 following the second implantation. The eye with the greater amount of astigmatism was implanted first (first operative eye). The second eye implant was intended to occur within 30 days after the first eye implant but not prior to 7 days after the first eye implant. Both eyes needed to qualify under inclusion/exclusion criteria at the preoperative visit. If the first eye was excluded during surgery, the second eye was not eligible. If the second eye was excluded during surgery, only the first eye was followed.